1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Binosto

Discussion in 'Mission Pharmacal' started by Anonymous, Nov 19, 2012 at 4:49 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Eerie how similar this is to Cambia Launch. Anyone else getting nervous?
     

  2. Anonymous

    Anonymous Guest

    Wasn't here for that launch, how did it go? Yes getting nervous.
     
  3. Anonymous

    Anonymous Guest

    Makes me want to hang a hat on a bums pecker
     
  4. Anonymous

    Anonymous Guest

    Stay close to the customers that know you. Don't fall in the trap of reach and frequency and ask for generic switches. Don't get stuck on apricot.
     
  5. Anonymous

    Anonymous Guest

    I hate this product. Once again failed to do adequate pre launch research. And these weekly Binosto calls are getting real annoying.
     
  6. Anonymous

    Anonymous Guest

    I agree. What were they thinking? And with the generic intrusion into our other product markets, I must say that I am getting concerned about keeping my head above the water.
     
  7. Anonymous

    Anonymous Guest

    Cambia was a smoldering disaster and a massive bust, one of Wild Card's smoldering turd piles. Is he still banging the inventiv rep in Jersey? Although I'm sure the barely lingual bear was right behind it too. You know the 2nd generation usually runs their dad's company into the ground repeatedly at high speed. What a horrible company to work for.
     
  8. Anonymous

    Anonymous Guest

    This drug is a joke- doctors know it and call it a "me too" drug. C'mon- no studies and crappy manged care. Mission got greedy and jumped to fast on this. Typical "small Pharma" mistake.
     
  9. Anonymous

    Anonymous Guest

    I believe Mr. Herring chooses the products we sell...
     
  10. Anonymous

    Anonymous Guest

    That's just what a doctor want some annoying little sales rep bugging them every week with some crappy product. You people are killing the industry
     
  11. Anonymous

    Anonymous Guest

    How are sales going with this great new novel product ?